FULC
What one share of Fulcrum Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need.
Fulcrum Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.21 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.94 |
| Cash and investments | $0.64 |
| Book value | $4.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$31.14 | $7.14 | −$25.09 | — | −$40.10 |
| 2019 | — | −$8.13 | $0.08 | −$3.65 | — | — |
| 2020 | $0.35 | −$2.79 | $0.05 | −$2.17 | — | $3.41 |
| 2021 | $0.54 | −$2.29 | $0.05 | −$2.27 | — | $5.21 |
| 2022 | $0.14 | −$2.44 | $0.04 | −$2.20 | — | $3.82 |
| 2023 | $0.05 | −$1.59 | $0.01 | −$1.49 | — | $3.80 |
| 2024 | $1.29 | −$0.16 | $0.00 | −$0.04 | — | $4.50 |
| 2025 | $0.00 | −$1.18 | $0.01 | −$0.95 | — | $5.24 |